The Cell & Gene Meeting on the Mediterranean is a two-day conference bringing together the entire cell and gene therapy community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, this program will feature expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and 50+ dedicated presentations by the leading publicly traded and privately held companies in the space.
Organised by Danish Stem Cell Society (DASCS) - the conference covers topics including hematopoietic stem cells, tissue regeneration – in vitro & in situ, commercialisation of stem cell therapies, cancer stem cells & precision oncology, stem cells in drug development.
Join ISBER in its first ever Annual Meeting in Asia. Network with colleagues, see keynote speakers from a global community of biorepository specialists and take part in workshops, social events and fun.
VISIT US ON STAND NUMBER: 61/70
Europe’s most important advanced therapies event with 1000+ attendees and 300+ speakers with both a conference and expo. Covering Gene Therapy, Gene Edited Cell Therapies, Stem Cells & Regenerative Medicine, each stage of development of cell, gene and immunotherapy; all the way from bioprocessing through clinical translation to reimbursement, market access and delivery to patient.
VISIT US ON STAND NUMBER: 16
As the flagship European trade show for innovative laboratory equipment and the optimization of laboratory workflows, LABVOLUTION covers the entire spectrum of lab technology and highlights the new directions and developments relevant to all user sectors.
VISIT US ON STAND NUMBER: B71, HALL 19
There is growing excitement and momentum in the field fuelled by two approved CAR-T products moving full steam ahead to global approval. However, despite these amazing achievements, both drugs are currently struggling on the market and have only treated a handful of patients to date due to challenges in manufacturing scale up, the ability to meet patient demands alongside payers and healthcare providers who are unable to make this therapy widely available. The CAR-TCR Summit promises to encapsulate this excitement whilst outlining the key challenges limiting commercial and clinical products, providing you with a comprehensive understanding of the full pharmaceutical value chain of CAR-TCR therapies.
VISIT US ON STAND NUMBER: 81